Prevalence of higher-grade dysplasia in persistently high-risk human papillomavirus positive, cytology negative women after introduction of the new cervical cancer screening in Germany.
Pregnancy
Humans
Female
Male
Uterine Cervical Neoplasms
/ diagnosis
Human Papillomavirus Viruses
Early Detection of Cancer
Retrospective Studies
Prevalence
Papillomavirus Infections
/ diagnosis
Uterine Cervical Dysplasia
/ epidemiology
Papillomaviridae
/ genetics
Colposcopy
Human papillomavirus 16
Mass Screening
CIN
Cervical cancer screening
Colposcopy
Negative cytology
VaIN
hrHPV
Journal
Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
19
10
2022
accepted:
10
02
2023
medline:
18
4
2023
pubmed:
2
3
2023
entrez:
1
3
2023
Statut:
ppublish
Résumé
According to the recently implemented organized cervical cancer screening program in Germany, women older than 35 years with negative cytology but persistent high-risk human papilloma virus (hrHPV) infection > 12 months should be referred to colposcopy for further evaluation. This study aimed to present and dissect colposcopic and histopathological findings with particular focus on associated hrHPV genotypes. This study is a retrospective analysis of clinical data from 89 hrHPV positive patients with normal cytology who underwent colposcopic examination at a certified dysplasia outpatient clinic in Germany in 2021. While 38 (43%) women had a normal colposcopic finding, 45 (51%) had minor and 6 (7%) major changes. Thirty-one (35%) of the women were HPV 16 and/or HPV 18 positive and 58 (65%) women were positive for other hrHPV only. Among patients who underwent colposcopy with biopsies (in case of an abnormal finding or type 3 transformation zone, n = 68), eight (12%) had cervical intraepithelial neoplasia (CIN) 3 and six (9%) had CIN 2. The proportion of women diagnosed with CIN 3 varied among different hrHPV genotypes (HPV 16: 11%, HPV 18: 33%, HPV 31: 27%, HPV 33: 33%, HPV 52: 33%). Persistently hrHPV positive women with negative cytology are at increased risk of being diagnosed with CIN 3. As CIN 3 prevalence seems to differ with regard to hrHPV strain, immediate HPV genotyping for risk stratification and subsequent early referral for colposcopy might constitute a feasible strategy.
Identifiants
pubmed: 36854989
doi: 10.1007/s10552-023-01677-z
pii: 10.1007/s10552-023-01677-z
pmc: PMC10105660
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
469-477Informations de copyright
© 2023. The Author(s).
Références
J Low Genit Tract Dis. 2009 Jul;13(3):137-44
pubmed: 19550210
Int J Clin Oncol. 2017 Oct;22(5):921-926
pubmed: 28451844
N Engl J Med. 2007 Oct 18;357(16):1589-97
pubmed: 17942872
J Low Genit Tract Dis. 2011 Jul;15(3):180-8
pubmed: 21436729
Cancer Epidemiol Biomarkers Prev. 2011 Jul;20(7):1398-409
pubmed: 21602310
Int J Cancer. 2014 Aug 1;135(3):624-34
pubmed: 24226935
J Clin Microbiol. 2011 Nov;49(11):3983-5
pubmed: 21880968
Br J Cancer. 2005 Oct 17;93(8):862-7
pubmed: 16189520
J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88
pubmed: 20841605
Acta Obstet Gynecol Scand. 2021 Mar;100(3):394-402
pubmed: 33566361
Obstet Gynecol. 2014 Oct;124(4):670-678
pubmed: 25198268
Br J Cancer. 2007 Jul 2;97(1):129-32
pubmed: 17551490
Int J Cancer. 2018 Aug 15;143(4):735-745
pubmed: 29341110
Int J Cancer. 2012 Feb 1;130(3):602-10
pubmed: 21400507
Diagn Cytopathol. 2021 Feb;49(2):267-272
pubmed: 33006823
Lancet Infect Dis. 2007 Jul;7(7):453-9
pubmed: 17597569
Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1268-73
pubmed: 16835322
Int J Gynaecol Obstet. 2016 Mar;132(3):266-71
pubmed: 26643302
Gynecol Oncol. 2019 Dec;155(3):436-443
pubmed: 31604662
J Med Virol. 2022 Feb;94(2):737-744
pubmed: 34460120
Obstet Gynecol. 2010 Dec;116(6):1324-1331
pubmed: 21099598
JAMA. 2018 Jul 3;320(1):43-52
pubmed: 29971397
Prev Med. 2017 May;98:33-35
pubmed: 28279260
Lancet. 2007 Sep 8;370(9590):890-907
pubmed: 17826171
Diagn Cytopathol. 2021 Apr;49(4):480-486
pubmed: 33528903
J Low Genit Tract Dis. 2020 Apr;24(2):102-131
pubmed: 32243307
Int J Cancer. 2019 Apr 15;144(8):1975-1982
pubmed: 30246864
J Low Genit Tract Dis. 2010 Oct;14(4):346-51
pubmed: 20885163
Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1274-80
pubmed: 16835323
Clin Microbiol Infect. 2020 May;26(5):579-583
pubmed: 31539637
Cancers (Basel). 2021 Jun 29;13(13):
pubmed: 34209851
Gynecol Oncol. 2003 Jun;89(3):424-8
pubmed: 12798706
Cancer Causes Control. 2014 Dec;25(12):1669-76
pubmed: 25296710
Arch Gynecol Obstet. 2022 Jan;305(1):87-93
pubmed: 34561716
Obstet Gynecol. 2012 Jul;120(1):166-72
pubmed: 22914406
Int J Clin Oncol. 2015 Jun;20(3):579-85
pubmed: 25145298
Int J Cancer. 2014 Sep 15;135(6):1408-16
pubmed: 24519782
BJOG. 2009 Oct;116(11):1506-14
pubmed: 19583712
BMC Womens Health. 2021 Nov 19;21(1):394
pubmed: 34798899
Int J Cancer. 2011 Jun 15;128(12):2898-910
pubmed: 20734388
Lancet Oncol. 2010 Mar;11(3):249-57
pubmed: 20089449
J Natl Cancer Inst. 2009 Jan 21;101(2):88-99
pubmed: 19141778
BMJ. 2016 Jul 28;354:i3633
pubmed: 27469988
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
Lancet Oncol. 2011 Sep;12(9):880-90
pubmed: 21865084
Lancet Oncol. 2012 Jan;13(1):78-88
pubmed: 22177579
Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):75-8
pubmed: 18760872
Int J Gynaecol Obstet. 2021 Aug;154(2):227-232
pubmed: 33411347
J Low Genit Tract Dis. 2021 Jul 1;25(3):221-231
pubmed: 34176914
Int J Cancer. 2015 Jul 1;137(1):193-203
pubmed: 25471319
Health Technol Assess. 2009 Nov;13(51):1-150, iii-iv
pubmed: 19891902
J Obstet Gynaecol Res. 2021 Feb;47(2):720-725
pubmed: 33314453
Obstet Gynecol. 2006 Aug;108(2):264-72
pubmed: 16880294